Royal Bank of Canada’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Sell |
109
-65,578
| -100% | -$287K | ﹤0.01% | 7038 |
|
|
2025
Q4 | $316K | Sell |
65,687
-171,142
| -72% | -$770K | ﹤0.01% | 4487 |
|
|
2025
Q3 | $1.07M | Sell |
236,829
-30,358
| -11% | -$111K | ﹤0.01% | 3932 |
|
|
2025
Q2 | $825K | Buy |
267,187
+204,942
| +329% | +$681K | ﹤0.01% | 4066 |
|
|
2025
Q1 | $218K | Buy |
62,245
+28,249
| +83% | +$94.2K | ﹤0.01% | 4634 |
|
|
2024
Q4 | $111K | Buy |
33,996
+17,621
| +108% | +$64.8K | ﹤0.01% | 5269 |
|
|
2024
Q3 | $63K | Sell |
16,375
-60,413
| -79% | -$232K | ﹤0.01% | 5587 |
|
|
2024
Q2 | $237K | Buy |
76,788
+3,642
| +5% | +$10.9K | ﹤0.01% | 4622 |
|
|
2024
Q1 | $188K | Sell |
73,146
-34,073
| -32% | -$88.2K | ﹤0.01% | 4738 |
|
|
2023
Q4 | $268K | Sell |
107,219
-8,955
| -8% | -$17.5K | ﹤0.01% | 4840 |
|
|
2023
Q3 | $236K | Buy |
116,174
+106,409
| +1,090% | +$223K | ﹤0.01% | 4647 |
|
|
2023
Q2 | $22K | Sell |
9,765
-82,014
| -89% | -$213K | ﹤0.01% | 6154 |
|
|
2023
Q1 | $277K | Sell |
91,779
-2,064
| -2% | -$5.82K | ﹤0.01% | 4360 |
|
|
2022
Q4 | $218K | Buy |
93,843
+1,302
| +1% | +$3.12K | ﹤0.01% | 4798 |
|
|
2022
Q3 | $177K | Sell |
92,541
-30,426
| -25% | -$71.6K | ﹤0.01% | 4872 |
|
|
2022
Q2 | $334K | Sell |
122,967
-7,208
| -6% | -$18.4K | ﹤0.01% | 4394 |
|
|
2022
Q1 | $388K | Sell |
130,175
-17,915
| -12% | -$54.8K | ﹤0.01% | 4484 |
|
|
2021
Q4 | $576K | Buy |
148,090
+3,653
| +3% | +$14.2K | ﹤0.01% | 4335 |
|
|
2021
Q3 | $620K | Buy |
144,437
+85,542
| +145% | +$285K | ﹤0.01% | 4172 |
|
|
2021
Q2 | $179K | Buy |
58,895
+58,317
| +10,089% | +$181K | ﹤0.01% | 5167 |
|
|
2021
Q1 | $2K | Sell |
578
-14,798
| -96% | -$57.1K | ﹤0.01% | 7213 |
|
|
2020
Q4 | $55K | Buy |
15,376
+1,497
| +11% | +$5.24K | ﹤0.01% | 5615 |
|
|
2020
Q3 | $43K | Buy |
13,879
+5,610
| +68% | +$17.1K | ﹤0.01% | 5404 |
|
|
2020
Q2 | $15K | Buy |
8,269
+5,856
| +243% | +$9.58K | ﹤0.01% | 5682 |
|
|
2020
Q1 | $3K | Buy |
2,413
+1,130
| +88% | +$3.06K | ﹤0.01% | 6164 |
|
|
2019
Q4 | $3K | Sell |
1,283
-5,969
| -82% | -$9.66K | ﹤0.01% | 6465 |
|
|
2019
Q3 | $11K | Buy |
7,252
+642
| +10% | +$1.11K | ﹤0.01% | 5737 |
|
|
2019
Q2 | $14K | Buy |
6,610
+39
| +0.6% | +$100 | ﹤0.01% | 5877 |
|
|
2019
Q1 | $23K | Sell |
6,571
-202
| -3% | -$775 | ﹤0.01% | 5584 |
|
|
2018
Q4 | $26K | Sell |
6,773
-4,283
| -39% | -$21.1K | ﹤0.01% | 5445 |
|
|
2018
Q3 | $104K | Buy |
11,056
+2,983
| +37% | +$29.6K | ﹤0.01% | 4833 |
|
|
2018
Q2 | $60K | Sell |
8,073
-6,926
| -46% | -$41.2K | ﹤0.01% | 5069 |
|
|
2018
Q1 | $75K | Buy |
14,999
+4,104
| +38% | +$21.7K | ﹤0.01% | 4847 |
|
|
2017
Q4 | $55K | Buy |
10,895
+540
| +5% | +$3.17K | ﹤0.01% | 5121 |
|
|
2017
Q3 | $64K | Sell |
10,355
-3,500
| -25% | -$15K | ﹤0.01% | 5276 |
|
|
2017
Q2 | $50K | Sell |
13,855
-125
| -0.9% | -$430 | ﹤0.01% | 5115 |
|
|
2017
Q1 | $46K | Sell |
13,980
-7,250
| -34% | -$20.1K | ﹤0.01% | 5195 |
|
|
2016
Q4 | $52K | Buy |
21,230
+8,280
| +64% | +$24.1K | ﹤0.01% | 5228 |
|
|
2016
Q3 | $45K | Sell |
12,950
-240
| -2% | -$938 | ﹤0.01% | 5203 |
|
|
2016
Q2 | $46K | Sell |
13,190
-400
| -3% | -$1.69K | ﹤0.01% | 5162 |
|
|
2016
Q1 | $56K | Sell |
13,590
-1,860
| -12% | -$6.64K | ﹤0.01% | 5062 |
|
|
2015
Q4 | $68K | Sell |
15,450
-54,850
| -78% | -$301K | ﹤0.01% | 5156 |
|
|
2015
Q3 | $428K | Buy |
70,300
+2,240
| +3% | +$19.9K | ﹤0.01% | 3673 |
|
|
2015
Q2 | $808K | Buy |
68,060
+35,133
| +107% | +$535K | ﹤0.01% | 3114 |
|
|
2015
Q1 | $575K | Buy |
32,927
+3,802
| +13% | +$77.9K | ﹤0.01% | 3378 |
|
|
2014
Q4 | $442K | Buy |
29,125
+13,075
| +81% | +$226K | ﹤0.01% | 3697 |
|
|
2014
Q3 | $340K | Sell |
16,050
-17,540
| -52% | -$286K | ﹤0.01% | 3812 |
|
|
2014
Q2 | $439K | Buy |
33,590
+13,560
| +68% | +$192K | ﹤0.01% | 3536 |
|
|
2014
Q1 | $430K | Buy |
20,030
+1,900
| +10% | +$34.1K | ﹤0.01% | 3462 |
|
|
2013
Q4 | $144K | Hold |
18,130
| – | – | ﹤0.01% | 4367 |
|
|
2013
Q3 | $127K | Sell |
18,130
-780
| -4% | -$4.29K | ﹤0.01% | 4337 |
|
|
2013
Q2 | $88K | Buy |
+18,910
| New | +$89.5K | ﹤0.01% | 4375 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Royal Bank of Canada's ABUS Position: Q1 2026 in Review
Royal Bank of Canada reduced its Arbutus Biopharma (ABUS) stake by 100% in Q1 2026, selling an estimated $287K and leaving 109 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7038.
Royal Bank of Canada first reported a position in ABUS in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.07M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Royal Bank of Canada held 109 shares of Arbutus Biopharma worth $0 as of Q1 2026.
- Royal Bank of Canada sold 65,578 Arbutus Biopharma shares in Q1 2026, an estimated $287K.
- Arbutus Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7038 holding.
- Royal Bank of Canada first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Arbutus Biopharma position peaked at $1.07M in Q3 2025.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.